Skip to main content

Table 1 Comparison of the general characteristics of patients with and without elevated FF-FGF13

From: Intrafollicular fibroblast growth factor 13 in polycystic ovary syndrome: relationship with androgen levels and oocyte developmental competence

Characteristics Elevated FF-FGF13  
Yes No P values
FF-FGF13 (pg/mL) 143.22 (119.11–190.27) 70.03 (53.20–86.94)
n 19 56
Age (years) 28.0 (23.0–33.0) 27.0 (25.0–30.0) 0.69
BMI (kg/m2) 22.6 (20.2–24.0) 20.3 (19.0–23.5) 0.06
PCOS, n (%) 14 (73.7) 29 (51.8) 0.095
Increased ovarian volume, n (%) 13 (68.2) 21 (38.9) 0.021
FF-LH (IU/L) 2.73 (0.33–4.33) 0.94 (0.29–4.460) 0.57
FF-FSH (IU/L) 4.57 (3.50–6.78) 4.49 (3.36–5.55) 0.72
FF-TT (nmol/L) 51.90 (22.18–88.52) 24.71(16.32–43.44) 0.016
FF-FAI 1.86 (0.99–2.72) 0.95 (0.65–1.31) 0.014
FF-E2 (μg/L) 2028.00 (1218.00–3400.00) 1685.00 (1344.00–2353.00) 0.65
FF-P4 (mg/L) 27.62 (16.70–58.70) 39.88 (22.93–56.21) 0.21
FF-IL-6 (pg/mL) 5.39 (4.69–7.96) 5.74 (4.92–9.95) 0.71
FF-FGF21 (pg/mL) 16.48 (13.47–24.50) 13.97 (9.47–17.98) 0.023
  1. Data are given as the median (interquartile range) for skewed variables or as the number (proportion) for categorical variables. “Elevated” FF-FGF13 levels were defined as follicular levels in the upper quartile (i.e., ≥117.51 pg/mL). P values were accessed using Kruskal-Wallis tests (continuous variables) and χ2 tests (categorical variables). FGF13 fibroblast growth factor 13; BMI body mass index; PCOS polycystic ovary syndrome; FF follicular fluid; LH luteinizing hormone; FSH follicle-stimulating hormone; TT total testosterone; FAI free androgen index; E2: estradiol; P4: progesterone; IL6: interleukin-6; FGF21: fibroblast growth factor 21